Slovak
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
8 výsledky
Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
In preclinical studies Pevonedistat has shown significant single agent activity against mouse xenograft models of AML cell Line HL-60. Also this effect seemed to be synergistically enhanced by combining it with Azacitidine. In clinical arena, Pevonedistat has shown single agent activity in heavily
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Multiple Myeloma (MM) is a clonal B cell disorder characterised by a monoclonal plasma cell population in bone marrow, with bone pain, anaemia, hypercalcaemia, and kidney dysfunction as clinically presenting symptoms. Osseous involvement is one of the most predominant features of patients with MM;
Efficacy Study of Dexamethasone to Treat the Acute Respiratory Distress Syndrome
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
The acute respiratory distress syndrome (ARDS) is an inflammatory disease process of the lungs as a response to both direct and indirect insults, characterized clinically by severe hypoxemia, reduced lung compliance, and bilateral radiographic infiltrates. ARDS is caused by an insult to the
Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
PRIMARY OBJECTIVES:
I. To evaluate the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profile of AMG 386 (trebananib) when administered alone and in combination with low-dose cytarabine in adult patients with: untreated AML considered ineligible for standard induction
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Tumor hypoxia has been associated with resistance to chemotherapy and radiotherapy (Brown et al, 2004; Boyle 2006). TH-302, a hypoxia activated prodrug (HAP), exploits the hypoxic nature of tumors while having little or no effect on normal tissue. TH-302 belongs to a class of alkylating agents
PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
A single arm study defining the recommended dose of PR104 for each subpopulation in this patient population.
Following informed consent, subjects will undergo baseline evaluation with a history, physical exams, blood work, and disease assessment. Subjects will be assigned a dose of PR104 based on a
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Metastatic prostate adenocarcinoma is initially dependent on exogenous androgens for survival and growth; hence, androgen blockade is a key initial intervention for these patients. Whether by orchiectomy or by biochemical blockade, androgen deprivation produces objective regression of prostate
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Synopsis
Title of study
Treatment of acute promyelocytic leukemia (APL) with arsenic trioxide (ATO). A phase-IV study to assess the effectiveness and toxicity of ATO as well as the kinetics of minimal residual disease (MRD) in patients with first and subsequent hematological or molecular relapse of
Najkompletnejšia databáza liečivých bylín podporovaná vedou
- Pracuje v 55 jazykoch
- Bylinné lieky podporené vedou
- Rozpoznávanie bylín podľa obrázka
- Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
- Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
- Vyhľadajte liečivé byliny podľa ich účinkov
- Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi
Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume
